Multi-marker Testing -The Power of Diagnostic Panels - US Cardiology 2006

Login or register to view PDF.
Citation
US Cardiology 2006;2005:2(1):1-3

Pages

A Unique Approach to Diagnostics

Biosite Incorporated has always had a unique vision for medical diagnosis. Since its inception in 1988, the company has strived to provide healthcare professionals with innovative and accurate data that is essential to improving patient outcomes. By making this information rapidly availableÔÇösometimes right at the patientÔÇÖs bedsideÔÇöBiositeÔÇÖs diagnostic technologies address the challenges that undermine healthcare excellence, and assists physicians in diagnosing emergent and potentially catastrophic diseases.

In medicine, rapid diagnosis takes priority because treatment cannot be initiated without it. Patients in emergency departments, intensive care units (ICUs) and operating rooms (ORs) can decompensate rapidly or even die during the period of time it takes for traditional diagnostic testing. The last quarter of the 20th century has seen dramatic advancements in imaging, but laboratory testing has not seen similar improvements. The limitations in diagnostics for critical diseases have had a profound effect on the utilization of advanced therapeutics. Revolutionary therapies, such as clot-busting drugs and endovascular procedures for diseases, such as heart attack and stroke, are not widely utilized, even in patients who might benefit, because rapid diagnostics have not previously existed. In the time it takes for a patient to undergo magnetic resonance imaging (MRI) or computerized tomography (CT) and the results interpreted by trained medical specialists, valuable minutesÔÇöminutes that might separate therapeutic efficacy from absent benefitÔÇöcan be lost. Biosite believes that clinical outcomes can be improved and healthcare costs lowered through more widespread use of innovative therapeutics, made possible by a rapid, accurate diagnosis.

While the potential benefit from improved rapid diagnostics has been evident to many in the healthcare industry, a powerful and reliable discovery pathway for proteomics has been elusive. The standard industry model has been watchfully waiting, followed by the in-licensing of already developed single-biomarker tests; this is a model that Biosite views as secondary. Instead, the priority is to proactively identify important diseases that are inadequately served by existing technologies, and pursue the discovery of biomarkers independently and through collaborations. Research programs that combine in-house biomarker development with clinical trials at leading research hospitals are the hallmark of BiositeÔÇÖs approach, and hold the promise of identifying rapid diagnostic tests where previously nothing existed.

Pages